TY - JOUR
T1 - Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction
T2 - A meta-analysis
AU - Navarese, E. P.
AU - De Luca, G.
AU - Castriota, F.
AU - Kozinski, M.
AU - Gurbel, P. A.
AU - Gibson, C. M.
AU - Andreotti, F.
AU - Buffon, A.
AU - Siller-Matula, J. M.
AU - Sukiennik, A.
AU - De Servi, S.
AU - Kubica, J.
PY - 2011/10
Y1 - 2011/10
N2 - Background: The aim of the current study was to perform two separate meta-analyses of available studies comparing low-molecular-weight heparins (LMWHs) vs. unfractionated heparin (UFH) in ST-elevation myocardial infarction (STEMI) patients treated (i) with primary percutaneous coronary intervention (pPCI) or (ii) with PCI after thrombolysis. Methods: All-cause mortality was the pre-specified primary endpoint and major bleeding complications were recorded as the secondary endpoints. Relative risk (RR) with a 95% confidence interval (CI) and absolute risk reduction (ARR) were chosen as the effect measure. Results: Ten studies comprising 16286 patients were included. The median follow-up was 2months for the primary endpoint. Among LMWHs, enoxaparin was the compound most frequently used. In the pPCI group, LMWHs were associated with a reduction in mortality [RR (95% CI)=0.51 (0.41-0.64), P
AB - Background: The aim of the current study was to perform two separate meta-analyses of available studies comparing low-molecular-weight heparins (LMWHs) vs. unfractionated heparin (UFH) in ST-elevation myocardial infarction (STEMI) patients treated (i) with primary percutaneous coronary intervention (pPCI) or (ii) with PCI after thrombolysis. Methods: All-cause mortality was the pre-specified primary endpoint and major bleeding complications were recorded as the secondary endpoints. Relative risk (RR) with a 95% confidence interval (CI) and absolute risk reduction (ARR) were chosen as the effect measure. Results: Ten studies comprising 16286 patients were included. The median follow-up was 2months for the primary endpoint. Among LMWHs, enoxaparin was the compound most frequently used. In the pPCI group, LMWHs were associated with a reduction in mortality [RR (95% CI)=0.51 (0.41-0.64), P
KW - Low-molecular-weight heparin
KW - Percutaneous coronary intervention
KW - ST-elevation myocardial infarction
KW - Unfractionated heparin
UR - http://www.scopus.com/inward/record.url?scp=80053424432&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053424432&partnerID=8YFLogxK
U2 - 10.1111/j.1538-7836.2011.04445.x
DO - 10.1111/j.1538-7836.2011.04445.x
M3 - Article
C2 - 21777368
AN - SCOPUS:80053424432
VL - 9
SP - 1902
EP - 1915
JO - Journal of Thrombosis and Haemostasis
JF - Journal of Thrombosis and Haemostasis
SN - 1538-7933
IS - 10
ER -